ACL ASX · Health Care

Australian Clinical Labs Ltd

Announcements, last 12 months: 173
Price sensitive, last 12 months: 7
Followed on InvestorPA: Some (top 20% of companies)

Latest announcements

Released	Headline	Actions
21 Oct 2026, 3:05 PM	Ceasing to be a substantial holder
20 Oct 2026, 3:08 PM	Becoming a substantial holder
16 Oct 2026, 4:56 PM	Ceasing to be a substantial holder
15 Oct 2026, 5:43 PM	Becoming a substantial holder
12 Oct 2026, 3:26 PM	Ceasing to be a substantial holder
12 Oct 2026, 10:45 AM	Correction to Notice of Meeting for 2026 AGM
9 Oct 2026, 5:41 PM	Becoming a substantial holder
2 Oct 2026, 3:54 PM	Change of Auditor
22 Sep 2026, 8:16 AM	Appendix 4G
22 Sep 2026, 8:16 AM	2026 Annual Report

Sign in to see all ACL announcements.

Guidance history

17 Aug 2026	FY27 revenue guidance: $745m to $765m; Underlying EBIT: $67m to $73m
17 Aug 2026	FY26 total revenue: $735.8m, underlying profit: $35.2m, earnings per share: 18.33c
28 Feb 2025	ACL reaffirmed its FY25 guidance of revenue of $725M to $752M and underlying EBIT of $65M to $73M.

Sign in to see the full guidance history.

Most followed in Health Care

PME Pro Medicus Ltd
AHC Austco Healthcare Ltd
CSL CSL Ltd
RMD Resmed Inc
TLX TELIX Pharmaceuticals Ltd
CGS Cogstate Ltd
ALC Alcidion Group Ltd
CSX Cleanspace Holdings Ltd

Follow ACL to get its announcements emailed to you, with AI summaries, the full announcement and guidance history, and its most significant announcements.